The findings suggest that starting tirzepatide earlier if standard care is inadequate may provide stronger and more sustained metabolic benefits than other standard approaches, the researchers said in a statement
Important points for patients to understand: No proven link exists between GLP-1 medications and pancreatic cancer based on extensive research involving hundreds of thousands of patients Type 2 diabetes itself carries an increased risk of pancreatic cancer, independent of treatment The absolute risk of pancreatic cancer remains low, even in higher-risk populations Regular medical follow-up allows for monitoring of overall health and early detection of any concerns When to contact your GP or seek medical attention: Patients should be aware of symptoms that warrant prompt medical evaluation, including: Persistent severe abdominal pain , particularly if it radiates to the back (potential sign of pancreatitis) if this occurs, stop taking your GLP-1 medication and seek urgent medical advice via your GP, NHS 111, or 999 if severe Unexplained weight loss (not attributable to the expected effects of GLP-1 therapy) New-onset jaundice (yellowing of skin or eyes) this requires immediate medical attention Persistent nausea and vomiting Unexpected deterioration in diabetes control or new-onset diabetes without typical risk factors Making informed treatment decisions: Patients considering or currently taking GLP-1 receptor agonists should: Discuss any concerns about cancer risk openly with their healthcare provider Understand their individual risk factors for pancreatic disease Maintain regular follow-up appointments as recommended Report any new or concerning symptoms promptly Continue treatment as prescribed unless advised otherwise by a healthcare professional Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) Lifestyle factors that reduce pancreatic cancer risksuch as smoking cessation, maintaining a healthy weight, and moderating alcohol consumptionremain important regardless of medication use
Introduction Liver is the second most commonly transplanted organ, representing 23.3% of all transplant procedures worldwide ( Prompt identification and treatment of PTDM is crucial due to the 2-3-fold increased risk of rejection, infections, cardiovascular events and all-cause mortality in these patients ( To date, data on the glycemic targets for this population are limited
Retrieved 14 May 2022, from A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegm
